Context: The diagnosis of congenital hypogonadotropic hypogonadism (CHH) in prepuberty has always been challenging. Here, we aimed at studying the clinical and genetic features of paediatric CHH, especially the phenotype of hypospadias and dual defects (patients showing hypothalamic and/or pituitary defects and testicular hypoplasia), so as to have a better understanding of CHH.
| INTRODUCTION
Congenital hypogonadotropic hypogonadism (CHH) results from deficiency in the production, secretion or action of gonadotrophinreleasing hormone (GnRH).
1 Patients with CHH presented with micropenis and/or cryptorchidism, absent or delayed puberty or infertility.
Some patients also exhibit other developmental anomalies, including cleft lip, dental agenesis, ear anomalies, congenital hearing impairment, renal agenesis, bimanual synkinesis. Patients presenting with anosmia or hyposmia is termed as Kallmann syndrome (KS).
2 CHH affects approximately 1-10 per 100 000 newborns, with approximately two-third and one-third of cases arising from KS and idiopathic HH, respectively. 1 CHH is genetically heterogeneous, with more than 31 different genes being implicated in Kallmann syndrome and/or nHH to date, which represents 50% of all cases, according to the CHH consensus published in 2015. 3 However, the list of candidate genes continues to grow.
4
Hypogonadism can be divided into 3 types: central (hypothalamicpituitary), primary (testicular) and combined forms (hypothalamicpituitary and testicular, the so-called dual defect form). CHH occurs due to the impaired production of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secondary to GnRH deficiency or due to pituitary defects (central hypogonadism), while deficiency of GnRH or gonadotrophins may lead to the failure of testicular development. 5 However, in some cases, both the hypothalamic-pituitary axis and the testes are affected simultaneously. These "dual" conditions are characterized by a lack of gonadotrophin elevation during puberty or adulthood despite the low testicular secretion of androgens and/ or inhibin B. Hitherto, the presence of dual defects in CHH subjects has only been demonstrated in one previous study, which was in the context of GnRH pump therapy. 6 A systematic analysis of the presence of dual defects in CHH men is lacking. In this study, we utilized the human chorionic gonadotrophin (hCG) stimulation test to assess potential testicular defects in paediatric CHH subjects.
Male neonates and infants suffering from CHH may present with micropenis and/or cryptorchidism, 7 which makes it possible to identify CHH in early childhood. Currently, genetic testing provides further evidence for the prepubertal diagnosis of CHH. 8 In contrast, hypospadias is caused by abnormal urethral closure during the early weeks of embryonic development, while urethral closure is often regulated by testosterone induced by hCG instead of gonadotrophins. Therefore, patients with hypospadias are often excluded from the diagnosis of CHH. 3 However, we have previously described KS patients with hypospadias in clinical practice 9 and observed that some genes that are involved in CHH could also be candidate genes for hypospadias.
10-14
The same signalling pathway plays a critical role in GnRH neuron ontogeny and development of the olfactory system. 16, 17 One possible reason for this interesting phenomenon is that CHH genes could contribute to DSD, but another possibility is that these patients may be diagnosed with CHH during follow-up. We have observed some patients with CHH who presented with micropenis with or without cryptorchidism or hypospadias; hence, we deduce that hypospadias may be a rare sign of CHH.
In this study, we present data of 64 male CHH cases whose clinical information was examined by the same paediatric endocrinologist and systematically analysed according to the clinical features and genetic results. In addition to establishing the phenotypic spectrum, we also analysed the prevalence of the dual defect in CHH subjects and correlated them with the genetic results.
| PATIENTS AND METHODS

| Patients
We selected 64 male CHH Han-Chinese patients who were seen at the Endocrinology outpatient clinic at Beijing Children's Hospital be- 
| Inclusion criteria
| Exclusion criteria
| Human chorionic gonadotrophin and LHRH stimulation tests
The hCG standard and LHRH stimulation tests were performed as previously described. 18 For the hCG prolonged test, hCG 1000 U was injected every other day for a total of 10 doses and serum testosterone level checked on the 20th day. A serum testosterone ≥3.47 nmol/L (100 ng/dL) was considered a good response, and a level of <3.47 nmol/L was considered a poor response.
19,20
| DNA sequencing
Overall, there were 164 genes (all CHH genes listed in reference 3
were included) in our gonadal panel, and the genes were obtained by referencing the OMIM and HGMD databases and entering the keywords "congenital hypogonadotropic hypogonadism," "idiopathic GnRH deficiency," "complex hypogonadism," "Kallmann syndrome,"
"gonad dysgenesis," "micropenis," "cryptorchidism," "hypospadias"
and "disorders of sex development" in Pubmed. DNA was extracted from peripheral blood leucocytes of patients and their parents and siblings, and the NEXTSEQ 500 sequencer (Illumina Corporation, San Diego, CA, USA) was used to filter out all possible pathogenic missense, frameshift and splice site mutations. Design primers and Sanger sequencing were used to verify the mutations of samples from the same family. Missense mutations were assessed for predicted pathogenicity using polyphen-2, sift and mutationtaster software packages; both frameshift and splicing site mutations were considered pathogenic mutations. Each mutation was contrasted to those in exac, snp databases and mutations of minor allele frequency (MAF) <1% in East Asian people. In addition, we checked the pathogenicity of the mutations in ClinVar (http://www.ncbi.nlm.nih.gov/clinvar).
| Hormone detection
Luteinizing hormone, FSH and testosterone were detected using enzyme-enhanced chemiluminescence immunoassay (Immulite 2000, Siemens Corporation, Munich, Germany).
| Statistical analysis
A chi-square test of four-grid data was used when comparing testosterone levels after the hCG stimulation test and PROKR2 frequency between dual and pure HH. Data analysis was performed using statistical product and service solutions 17.0 software (spss, International Business Machines Corporation, Armonk, NY, USA).
| RESULTS
| Demographic summary
A total of 64 cases were diagnosed definitively using the inclusion criteria. Forty-seven patients were diagnosed with KS (73.4%), and 17 had nHH without any special syndrome features (eg Charge syndrome, PWS). One case was diagnosed within 6 months of birth, 41
cases were between 6 months and 14 years, and 22 cases were between 14 and 18 years.
| Clinical features
External genitalia morphology included isolated micropenis (35%), delayed puberty (12%), isolated cryptorchidism alone (7%) and mixed form (46%) (see Figure 1 and Table S1 ). Micropenis combined with cryptorchidism was the most common form (39%), followed by isolated micropenis. However, all forms of cryptorchidism, including the combined form, were the most common feature of CHH in our study (51.6%).
There was no significant difference when comparing testosterone 
| Genetic results
In the 51 patients who had genetic testing and Sanger sequenc- Figure 2 . The most commonly mutated genes were PROKR2 (17.6%, 9 cases, KS/nHH = 6/3), FGFR1 (13.7%, 7 cases, KS/nHH = 5/2) and CHD7 (7.8%, 4 cases, KS/nHH = 2/2), see Table S3 . Two cases (cases 57 and 59) were compound heterozygous mutations of the same gene (KISS1R, CHD7).
| Relationship between hypospadias and genotype
Case 7 had a FGF17 (p.Pro120Leu) missense mutation. He had hyposmia, and the MRI showed an abnormality. Two cases (23 and 57)
carried CHD7 missense mutations: one was diagnosed as KS and the other had CHD7 compound heterozygous mutations (p.Ala2732Thr; p.Ala2866Val), and his father had delayed puberty. Case 11 had a negative genetic result, and he was 14 years old and presented with stalled puberty that began at the age of 12 with testes 4-5 mL, but showed no progression in the following 2 years. See Figure 3 and Table S4 .
| Relationship between dual defects and genotype
Six of the 15 dual CHH patients carried the PROKR2 mutation. This was a higher frequency compared to the other 36 patients (6/15 vs 3/36, P = .021). Furthermore, 4 PROKR2 mutations (including 2 KS) were at the same allele, p.Trp178Ser. The other 2 dual patients (including 1 KS) carried the FGFR1 mutation; see Figure 3 . However, 4 cases had negative results, and 3 patients with KS did not undergo genetic testing.
F I G U R E 3
The correlation between various clinical phenotypes and genotype of 4 cases with hypospadias and 15 dual HH. Note: #:Means compound heterozygous mutation. *:p.Trp178Ser.There were 6 dual cases had same gene PROKR2 mutations, which was higher than that in pure HH patients (3/36, p=0.021), and 4 of them at the same mutation site. 
| DISCUSSION
The 64 young male paediatric patients included in this study were diagnosed with HH, and their clinical and genetic data were studied over 8 years in our hospital. The proportion of patients with KS was 73.4%, which is similar to that previously reported by endocrinologists in teenage and adult healthcare institutions. 21 In our study, we also found some patients in whom HH was combined with hearing impairment, renal agenesis and synkinesis. The sense of smell of 12 patients with KS was inconsistent with MRI analysis of the olfactory bulb, which has been reported previously. 15, 22, 23 Mutations in the genes PROKR2 (17.6%), FGFR1 (13.7%), CHD7 (7.8%) and KAL1 (5.9%)
were found to be common in the patients of this paediatric study, whereas FGFR1, CHD7, GNRHR and KAL1 were the most common genetic causes in a previous study of adult patients where the proportion each was no more than 10%. 24 This might indicate that those diagnosed in a paediatric clinic have more severe phenotypes. and small testes compared to boys who did not carry mutations in
PROKR2
. 28 In addition, the study showed no obvious differences in the testes of Prokr2 +/− heterozygous mice compared with wild-type mice 27 . In our study, we found a high frequency of PROKR2 mutations, and some patients carried the same mutation, especially in dual patients. There were 2 patients harbouring only an FGFR1 mutation. So far, we have been unable to explain the pathogenicity of dual defects and believe that the mechanism should be studied further.
In conclusion, KS-related phenotypes are the main basis of CHH diagnosed during childhood. Micropenis alone or in combination with cryptorchidism provides an important clue for CHH. Paediatric patients may be found to have dual defects in CHH, and hypospadias cannot exclude a diagnosis of CHH. PROKR2 (17.6%), FGFR1 (13.7%), CHD7 (7.8%), KAL1 (5.9%) and IL17RD (5.9%) are common CHH genes. Testicular function may be impaired earlier than expected, so it is meaningful to evaluate dual defects in children and follow up their infertility into adulthood. For adolescents, a genetic test could confirm the diagnosis, while for young patients below 14 years of age, and especially for infants up to 6 months of age, genetic testing may be obligatory.
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